{
    "name": "regadenoson",
    "comment": "Rx",
    "other_names": [
        "Lexiscan"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/lexiscan-regadenoson-343762",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to inform a drug-associated risk"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, adverse developmental outcomes were observed with the administration to pregnant rats and rabbits during organogenesis only at doses that produced maternal toxicity"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information on presence of regadenoson in human milk, effects on breastfed infant, or on milk production; because of the potential risk of serious cardiac reactions in breastfed infant, advise the nursing mother to pump and discard breast milk for 10 hours after administration of the drug"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Second- or third-degree AV block, or sinus node dysfunction (unless patient has a functioning artificial pacemaker installed)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Appropriate bronchodilator therapy and resuscitative measures should be available prior to and following therapy; adhere to recommended duration of injection; longer injection times may increase duration and magnitude of increase in coronary blood flow",
                "QT prolongation has occurred shortly after administration in postmarketing surveillance",
                "Adenosine receptor agonists can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia requiring intervention",
                "Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria, and rashes have occurred",
                "Adenosine receptor agonists may cause dyspnea, bronchoconstriction, and respiratory compromise; caution with asthma or bronchoconstrictive disease; appropriate bronchodilator therapy and resuscitative measures should be available prior to and following therapy administration",
                "Nucleoside transport inhibitors (eg, dipyridamole) and potentiate the vasoactive effects of regadenoson; withhold for 5 half-lives before regadenoson administration",
                "Methylxanthines (eg, caffeine, theophylline) are adenosine receptor antagonists and inhibit regadenosonâ€™s vasoactive effects; withhold methylxanthines for 5 half-lives before regadenoson administration",
                "Aminophylline may increase risk of seizures associated with regadenoson injection; aminophylline may increase risk of seizures associated with therapy; methylxanthine use is not recommended in patients who experience a seizure in association with this drug",
                "May lower seizure threshold; new-onset or recurrence of convulsive seizures has occurred following regadenoson injection; some seizures are prolonged and require emergent anticonvulsive management",
                "Hemorrhagic and ischemic cerebrovascular accidents have occurred; effects of including hypotension or hypertension may be associated with these adverse reactions",
                "New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter reported",
                "Adenosine receptor agonists induce arterial vasodilation and hypotension; risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency; in post-marketing experience, syncope, transient ischemic attacks and seizures have been observed",
                "Administration of adenosine receptor agonists may result in clinically significant increases in blood pressure in some patients; in post-marketing experience, cases of potentially clinically significant hypertension have been reported, particularly with underlying hypertension and when low-level exercise was included in the myocardial perfusion imaging"
            ],
            "specific": [
                {
                    "type": "Myocardial ischemia",
                    "description": [
                        "Fatal and nonfatal myocardial infarction (MI), ventricular arrhythmias, and cardiac arrest reported; avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability; these patients may be at greater risk of serious cardiovascular reaction",
                        "Cardiac resuscitation equipment and trained staff should be available before administering therapy; adhere to recommended duration of injection; as noted in an animal study, longer injection times may increase duration and magnitude of increase in coronary blood flow",
                        "If serious reactions occur, consider use of aminophylline, an adenosine antagonist, to shorten duration of increased coronary blood flow induced by the drug"
                    ]
                },
                {
                    "type": "Risk for myocardial infarction and death",
                    "description": [
                        "Avoid use for cardiac nuclear stress tests in patients with signs or symptoms of acute myocardial ischemia (eg, unstable angina, cardiovascular instability); use may increase risk of fatal MI",
                        "Screen all nuclear stress test candidates for risks"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "caffeine",
            "description": {
                "common": "caffeine decreases effects of regadenoson by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid methylxanthines for 12 hours before regadenoson administration."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dipyridamole",
            "description": {
                "common": "dipyridamole, regadenoson. Mechanism: unspecified interaction mechanism. Contraindicated. Regadenoson's effects may be changed; mfr. recommends avoiding dipyridamole for 2 days prior to administration."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "theophylline",
            "description": {
                "common": "theophylline decreases effects of regadenoson by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid methylxanthines for 12 hours before regadenoson administration."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Dyspnea",
            "percent": "28"
        },
        {
            "name": "Headache",
            "percent": "26"
        },
        {
            "name": "Rhythm conduction abnormalities",
            "percent": "26"
        },
        {
            "name": "Flushing",
            "percent": "16"
        },
        {
            "name": "PVCs",
            "percent": "14"
        },
        {
            "name": "Chest Discomfort",
            "percent": "13"
        },
        {
            "name": "Angina or ST segment depression",
            "percent": "12"
        },
        {
            "name": "Dizziness",
            "percent": "8"
        },
        {
            "name": "Chest pain",
            "percent": "7"
        },
        {
            "name": "PACs",
            "percent": "7"
        },
        {
            "name": "Nausea",
            "percent": "6"
        },
        {
            "name": "Ventricular conduction abnormalities",
            "percent": "6"
        },
        {
            "name": "Abdominal discomfort",
            "percent": "5"
        },
        {
            "name": "Dysgeusia",
            "percent": "5"
        },
        {
            "name": "Feeling hot",
            "percent": "5"
        },
        {
            "name": "First",
            "percent": "3"
        },
        {
            "name": "degree AV block",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "cardiac arrest",
            "percent": null
        },
        {
            "name": "respiratory arrest",
            "percent": null
        },
        {
            "name": "distress",
            "percent": null
        },
        {
            "name": "throat tightness",
            "percent": null
        },
        {
            "name": "and urticaria",
            "percent": null
        },
        {
            "name": "rashes",
            "percent": null
        },
        {
            "name": "atrial fibrillation",
            "percent": null
        },
        {
            "name": "seizures",
            "percent": null
        },
        {
            "name": "cardiovascular accidents",
            "percent": null
        },
        {
            "name": "stroke",
            "percent": null
        },
        {
            "name": "Cardiovascular",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "cardiac arrest",
            "percent": null
        },
        {
            "name": "ventricular arrhythmias",
            "percent": null
        },
        {
            "name": "supraventricular tachyarrhythmias including atrial fibrillation with rapid ventricular response",
            "percent": null
        },
        {
            "name": "new",
            "percent": null
        },
        {
            "name": "onset or recurrent",
            "percent": null
        },
        {
            "name": "atrial flutter",
            "percent": null
        },
        {
            "name": "heart block",
            "percent": null
        },
        {
            "name": "including third",
            "percent": null
        },
        {
            "name": "degree block",
            "percent": null
        },
        {
            "name": "asystole",
            "percent": null
        },
        {
            "name": "marked hypertension",
            "percent": null
        },
        {
            "name": "symptomatic hypotension in association with transient ischemic attack",
            "percent": null
        },
        {
            "name": "seizures and syncope",
            "percent": null
        },
        {
            "name": "Central nervous system",
            "percent": null
        },
        {
            "name": "Tremor",
            "percent": null
        },
        {
            "name": "seizure",
            "percent": null
        },
        {
            "name": "transient ischemic attack",
            "percent": null
        },
        {
            "name": "and cerebrovascular accident including intracranial hemorrhage",
            "percent": null
        }
    ]
}